

**Revised Draft Agenda**  
**Biocides Working Group Meeting I-2017**  
**17 – 25 January 2017**

ECHA Conference Centre (Annankatu 18, Helsinki)  
 Meeting room Margot Wallstrom (MW)  
 Meeting room K325

Coffee break 11:00-11:30  
 Lunch break 13:00-14:00  
 Coffee break 15:30-16:00

Tuesday 17 January	09:30-13:00	APCP WG (K325)
	14:00-18:00	
Wednesday 18 January	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Thursday 19 January	09:00-13:00	TOX WG (MW)
	14:00-18:00	
Wednesday 18 January	09:30-13:00	EFF WG (K325)
	14:00-18:00	
Thursday 19 January	09:00-13:00	EFF WG (K325)
	14:00-16:30	
Tuesday 24 January	09:00-13:00	ENV WG (MW)
	14:00-19:00	
Wednesday 25 January	08:30-13:00	ENV WG (MW)
	14:00-19:00	

## **Analytical methods and physico-chemical properties Working Group**

**Chair: Bernhard Krebs**

### **Item 1 – Welcome and apologies**

### **Item 2 – Administrative issues**

### **Item 3 – Agreement of the agenda**

*For agreement*

### **Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

### **Item 5 – Agreement of the draft minutes from WG-V-2016**

Meeting documents:

- *WGV2016\_APCP\_7-1\_draft minutes*
- *WGV2016\_APCP\_7-2\_draft minutes*
- *WGV2016\_APCP\_8-1\_draft minutes*
- *WGV2016\_APCP\_gen\_agenda\_items\_draft minutes*

*For agreement*

### **Item 6 – Follow-up of previous working group meetings**

#### **6.1 Follow-up of previous working group meetings**

### **Item 7 – Discussion of active substances**

#### **7.1 Propan-1-ol (eCA DE)**

PT 01, 02, 04

Meeting document: *WGI2017\_APCP\_7-1*

*For discussion/agreement*

#### **7.2 Imiprothrin (eCA UK)**

PT 18

Meeting document: *WGI2017\_APCP\_7-2*

*For discussion/agreement*

#### **7.3 Cholecalciferol (eCA SE)**

PT 14

Meeting document: *WGI2017\_APCP\_7-3*

*For discussion/agreement*

#### **7.4 Icaridin (eCA DK)**

PT 19

Meeting document: *WG-I-2017\_APCP\_7-4*

*For discussion/agreement*

## Item 8 – Technical and scientific issues

### 8.1 Peracetic acid “diluted” one or several active substance(s)

Meeting document: *WGI2017\_APCP-8-1*

*For discussion/agreement*

### 8.2 DDAC (C<sub>8-10</sub>), ADBAC (C<sub>12-14</sub>), ADBAC (C<sub>12-18</sub>) and ADEBAC (C<sub>12-14</sub>), early working group discussion

Meeting document: *WGI2017\_APCP-8-2*

*For discussion*

## Item 9 – AOB

### 9.1 Other information & lessons learned

SECR/WG members to inform and to reflect on the experience gained

*For information*

## Human Health Working Group

Chair: Antero Airaksinen

### Item 1 – Welcome and apologies

### Item 2 – Administrative issues

### Item 3 – Agreement of the agenda

*For agreement*

### Item 4 – Declarations of potential conflicts of interest in relation to the agenda

### Item 5 – Agreement of the draft minutes from WG-V-2016

Meeting documents:

- *WGV2016\_TOX\_6-1\_Draft minutes*
- *WGV2016\_TOX\_6-2\_Draft minutes*
- *WGV2016\_TOX\_6-3\_Draft minutes*
- *WGV2016\_TOX\_minutes\_draft.docx*

*For agreement*

### Item 6 – Discussion of active substances

#### 6.1 Propan-1-ol (eCA DE)

PT 1, 2, 4

Meeting document: *WGI2017\_TOX\_6-1*

*For discussion/agreement*

#### 6.2 Imiprothrin (eCA UK)

PT 18

Meeting document: *WGI2017\_TOX\_6-2*

*For discussion/agreement*

#### 6.3 Cholecalciferol (eCA SE)

PT 14

Meeting document: *WGI2017\_TOX\_6-3*

*For discussion/agreement*

#### 6.4 Icaridin (eCA DK)

PT 19

Meeting document: *WGI2017\_TOX\_6-4*

*For discussion/agreement*

**6.5 Silicon dioxides – AEC values (eCA FR)**

Silicon dioxide Kieselguhr

Pyrogenic, synthetic amorphous silicon dioxide, nano, surface treated

PT 18

Meeting document: *WGI2017\_TOX\_6-5*

*For discussion/agreement*

**Item 7 – Technical and guidance related issues**

**7.1 Update on guidance development**

SECR to inform

*For information*

**7.2 Update on Ad hoc Working Group - Human Exposure**

SECR to inform

*For information*

**(a) Recommendation of the Ad hoc Working Group – Human Exposure**

Teat disinfection products for veterinary hygiene (PT 3)

*For discussion/agreement*

**(b) Recommendation of the Ad hoc Working Group – Human Exposure**

Revision of recommendation 9: Hand disinfection in hospitals by professionals – inhalation and dermal exposure during hand disinfection

*For discussion/agreement*

**7.3 Update on Ad hoc Working Group – Assessment of residue transfer to food (ARTFood)**

SECR to inform

*For information*

**7.4 Data requirements for precursors of *in situ* generated active substances**

Discussion based on the input provided by MSCAs

Meeting documents: please see the input provided by MSCAs in the dedicated S-CIRCABC Newsgroup

*For discussion/agreement*

**Item 8 – AOB**

**8.1 Other information & lessons learned**

SECR/WG members to inform and to reflect on the experience gained

*For information*

**Efficacy Working Group**  
**Chair: Katarzyna Szymankiewicz**

**Item 1 – Welcome and apologies**

**Item 2 – Administrative issues**

**Item 3 – Agreement of the agenda**

*For agreement*

**Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

**Item 5 – Agreement of the draft minutes from WG-V-2016**

Meeting documents:

- WGV2016\_EFF\_6-1\_draft\_minutes.docx
- WGV2016\_EFF\_6-2\_draft\_minutes.docx
- WGV2016\_EFF\_draft\_minutes.docx

*For agreement*

**Item 6 – Discussion of active substances**

**6.1 Propan-1-ol (eCA DE)**

PT 01, 02, 04

Meeting document: WGI2017\_EFF\_6-1

*For discussion/agreement*

**6.2 Imiprothrin (eCA UK)**

PT 18

Meeting document: WGI2017\_EFF\_6-2

*For discussion/agreement*

**6.3 Cholecalciferol (eCA SE)**

PT 14

Meeting document: WGI2017\_EFF\_6-3

*For discussion/agreement*

**6.4 Icaridin (eCA DK)**

PT 19

Meeting document: WGI2017\_EFF\_6-4

*For discussion/agreement*

**6.5 Cyphenothrin (eCA EL)**

PT 18

Meeting document: WGI2017\_EFF\_6-5

*For discussion/agreement*

**6.6 DBNPA (eCA DK)**

PT 4

Meeting document: *WGI2017\_EFF\_6-6*

*For discussion/agreement*

**Item 7 – Technical and guidance related issues**

**7.1 Update on guidance development (ECHA)**

*For information*

**7.2 Appendix 4 of the PT8 efficacy guidance related to Annex A of EN 599-1 (FR)**

*For discussion*

**7.3 PT11&12 matrix claim (FR - tbc)**

*For discussion*

**7.4 Revision of Volume II, Part A - Information Requirements (ECHA)**

*For discussion*

**7.5 Appendix 4 of the PT1-5 Efficacy Guidance**

*For agreement*

**Item 8 – AOB**

**8.1 Aircraft disinfection (BE)**

*For discussion*

**8.2 TAB – proposals for inclusion**

*For discussion*

**8.3 Testing to prove that co-formulants are not active**

*For discussion*

**8.4 PT 14: Applications for major changes with lower concentration of an active substance (DE)**

*For discussion*

**8.5 Other information & lessons learned**

SECR/WG members to inform and to reflect on the experience gained

*For information*

**Environment Working Group**  
**Chair: Heike Schimmelpfennig**

**Item 1 – Welcome and apologies**

**Item 2 – Administrative issues**

**Item 3 – Agreement of the agenda**

*For agreement*

**Item 4 – Declarations of potential conflicts of interest in relation to the agenda**

**Item 5 – Agreement of the draft minutes from WG-V-2016**

Meeting documents:

- WGV2016\_ENV\_6-1\_Draft minutes
- WGV2016\_ENV\_6-2\_Draft minutes
- WGV2016\_ENV\_General\_Draft minutes

*For agreement*

**Item 6 – Discussion of active substances**

**6.1 Propan-1-ol (eCA DE)**

PT 01, 02, 04

Meeting document: WGI2017\_ENV\_6-1

*For discussion/agreement*

**6.2 Icaridin (eCA DK)**

PT 19

Meeting document: WGI2017\_ENV\_6-2

*For discussion/agreement*

**6.3 Cholecalciferol (eCA SE)**

PT 14

Meeting document: WGI2017\_ENV\_6-3

*For discussion/agreement*

**6.4 Imiprothrin (eCA UK)**

PT 18

Meeting document: WGI2017\_ENV\_6-4

*For discussion/agreement*



## Item 7 – Technical/guidance related issues (including AHEE members)

### 7.1 Update on guidance development and work of the AHEE (ECHA)

Meeting document: *WGI2017\_ENV\_7-1*

*For information*

### 7.2 Agreement of documents discussed at AHEE-1

**7.2a** Evaluation of the model SimpleTreat (DE)

**7.2b** Draft guide on PT 21 product authorisation (UK)

Meeting documents: *WGI2017\_ENV\_7-2a-b*

*For discussion/agreement*

### 7.3 Emission Scenario Document (ESD) for PT 6 (DE)

Meeting document: *WGI2017\_ENV\_7-3*

*For discussion/agreement*

### 7.4 AHEE related items taken up in the disinfection project (ECHA)

**7.4a** RTU scenarios for small scale applications in PT 1, 2 and 3

**7.4b** Conversion of surface area to volume when applying the biocidal product by e.g. vaporizing or fogging for PT 2

Meeting documents: *WGI2017\_ENV\_7-4a-b*

*For discussion/agreement*

### 7.5 Refinement of $f_{\text{house}}$ /scaling approach for PT 6.2, 7, 8, 9, 10 (city scenario, roof membranes (DE/ECHA)

Meeting document: *WGI2017\_ENV\_7-5*

*For discussion/agreement*

### 7.6 Open items related to exposure assessment in the frame of product authorisation (national/Union) (ECHA)

Meeting document: *WGI2017\_ENV\_7-6*

*For discussion/agreement*

### 7.7 PT 3 - Draft emission scenarios for disinfectants used in aquaculture (ECHA)

Meeting document: *WGI2017\_ENV\_7-7*

*For information/discussion*

### 7.8 Outcome of e-consultations initiated in Q4 2016 (DE, DK, UK)

eCAs having initiated e-consultations to report on the outcome

*For information*

## Item 8 – AOB

### 8.1 Other information & lessons learned

SECR/WG members to reflect on the experience gained

*For information*